Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by ...

Medically reviewed by Nicholas R. Metrus, MD Key Takeaways Huntington's disease is a genetic disorder that you can inherit from your parents.The symptoms of Huntington's disease typically start in a ...

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT ®-HD2 study of INGREZZA ® (valbenazine) ...

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive ...

Neurocrine Biosciences is a pharmaceutical company specializing in the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company recently submitted a proposal for the use ...

What is Huntington’s disease? Huntington's disease, a cause of dementia like Alzheimer's, is a neurodegenerative genetic disorder that leads to cognitive decline, psychiatric problems and affects ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile ...